查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611369

硬皮症診斷與治療市場：按診斷測試、藥物類型、治療方法、適應症分類 - 全球預測 2025-2030

Scleroderma Diagnostics & Therapeutics Market by Diagnostic Tests (Blood Tests, Imaging, Pulmonary Function Tests), Drug Type (Calcium Channel Blockers, Chelating Agents, Corticosteroids), Therapeutics, Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

硬皮症診斷與治療市場2023年估值為20.9億美元，預計2024年將達21.9億美元，複合年成長率為6.25%，到2030年預計將達32億美元。

硬皮症是一種慢性結締組織疾病，在診斷和治療方面提出了獨特的挑戰，市場範圍包括旨在控制疾病進展的先進檢測技術和治療方案。強力的診斷的必要性在於硬皮症的異質性，這需要準確和早期的檢測以將其與其他自體免疫疾病區分開來。應用領域包括血清學測定、成像技術和個人化治療計劃所必需的生物標記識別。最終使用領域範圍從臨床實驗室和研究機構到專科醫院。影響該市場的關鍵成長要素包括自體免疫疾病的日益普及、生物技術的進步帶來更精確的診斷以及對個人化醫療的日益重視。向生技藥品和免疫療法的轉變提供了顯著的機遇，新興市場醫療保健基礎設施的擴張也是如此。鼓勵公司投資致力於開發非侵入性診斷工具和標靶治療的研究。與學術機構的合作以及策略聯盟和合併可以提供競爭優勢並加速產品開發。然而，市場開拓受到高昂的研發成本、監管障礙和硬皮症阻礙了普遍有效的治療方法的發展。此外，由於硬皮症是一種罕見疾病，大規模臨床試驗帶來了挑戰，影響了資料可用性和市場規模。創新領域包括利用基因組研究和人工智慧來預測疾病進展，以及探索微生物組在調節自體免疫反應中的作用。儘管該市場的特點是高度專業化，並且有可能重新定義護理標準的突破機會，但永續成長將需要大量的科學、監管和經濟策略來應對這種情況。

主要市場統計
基準年[2023] 20.9億美元
預計年份 [2024] 21.9億美元
預測年份 [2030] 32億美元
複合年成長率（%） 6.25%

市場動態：快速發展的硬皮症診斷和治療市場的關鍵市場洞察

硬皮症診斷和治療市場正在因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 硬皮症患者病率不斷增加，需要有效的診斷技術和治療方法
    • 提高對硬皮症的認知並重視早期診斷
    • 增加開發新藥和治療方法的臨床試驗數量
  • 市場限制因素
    • 硬皮症治療相關的高成本
  • 市場機會
    • 影像診斷技術、生物標記識別等診斷技術的進步
    • 正在進行的研究以確定硬皮症的有效治療方法
  • 市場挑戰
    • 與治療硬皮症的藥物相關的副作用

波特五力：開拓硬皮症診斷與治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解硬皮症診斷和治療市場的外部影響

外部宏觀環境因素在塑造硬皮症診斷和治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解硬皮症診斷和治療藥物市場的競爭狀況

硬皮症診斷和治療市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV硬皮症診斷與治療市場中的定位矩陣供應商績效評估

FPNV定位矩陣是評估硬皮症診斷和治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製硬皮症診斷和治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對硬皮症診斷和治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 硬皮症患者病率不斷增加，需要有效的診斷技術和治療方法
      • 提高對硬皮症症狀和早期診斷重要性的認知
      • 增加臨床試驗以開發新藥和治療方法
    • 抑制因素
      • 硬皮症治療相關的高費用
    • 機會
      • 成像技術和生物標記識別等診斷技術的進步
      • 繼續研究以確定硬皮症的有效治療方法
    • 任務
      • 與治療硬皮症的藥物相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依診斷測試分類的硬皮症診斷與治療市場

  • 驗血
  • 影像
    • 電腦斷層掃描
    • MRI
    • X光檢查
  • 肺功能檢查
  • 皮膚切片檢查

第7章硬皮症診斷與治療藥物市場依藥物類型分類

  • 鈣離子通道阻斷劑
  • 螯合劑
  • 皮質類固醇
  • 內皮素受體促效劑
  • 免疫抑制劑
  • PDE-5抑制劑
  • 前列腺環素類似物

第八硬皮症硬皮症診斷與治療市場治療

  • 生物療法
  • 基因治療
  • 肺纖維化的治療
  • 雷諾現象的治療
  • 幹細胞移植

第9章硬皮症診斷與治療藥物市場（按適應症）

  • 本土化
  • 系統性的

第10章 北美和南美硬皮症診斷和治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區硬皮症診斷與治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲硬皮症診斷和治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • Antibodies Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bio-Rad Laboratories, Inc
  • Biogen Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc（GSK）
  • Merck & Co., Inc.
  • Myriad Genetics, Inc
  • Novartis AG
  • PerkinElmer Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi Genzyme
  • Takeda Pharmaceutical Company Limited
  • The Bristol-Myers Squibb Company
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc.
Product Code: MRR-8E22B61932B9

The Scleroderma Diagnostics & Therapeutics Market was valued at USD 2.09 billion in 2023, expected to reach USD 2.19 billion in 2024, and is projected to grow at a CAGR of 6.25%, to USD 3.20 billion by 2030.

Scleroderma, a chronic connective tissue disease, presents unique challenges in diagnostics and therapeutics, with the market scope encompassing advanced detection methodologies and therapeutic options aimed at managing the disease progression. The necessity of robust diagnostics lies in the heterogeneous nature of scleroderma, requiring precise and early detection to differentiate from other autoimmune conditions. Application areas include serological assays, imaging technologies, and biomarker identification, integral for personalized treatment plans. End-use sectors range from clinical laboratories and research institutions to specialty hospitals. Key growth factors influencing this market include increasing prevalence of autoimmune disorders, advancements in biotechnology leading to more precise diagnostics, and a growing emphasis on personalized medicine. The shift towards biologics and immunotherapies presents notable opportunities, as does the expanding healthcare infrastructure in emerging markets. Companies are recommended to invest in research focused on developing non-invasive diagnostic tools and targeted therapies. Collaborations with academic institutions for research, coupled with strategic partnerships or mergers, can offer competitive advantages and accelerate product development. However, market growth is challenged by high R&D costs, regulatory hurdles, and the complex pathophysiology of scleroderma that hampers the development of universally effective treatments. Additionally, the rarity of the disease poses challenges for large-scale clinical trials, impacting data availability and market scale. Innovation areas include genomic research and leveraging AI for predictive analytics in disease progression, as well as exploring the microbiome's role in autoimmune response modulation. The market nature is characterized by a high degree of specialization with significant opportunities for breakthroughs that could redefine standards of care but requires strategic navigation through scientific, regulatory, and economic landscapes to achieve sustainable growth.

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.19 billion
Forecast Year [2030] USD 3.20 billion
CAGR (%) 6.25%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Scleroderma Diagnostics & Therapeutics Market

The Scleroderma Diagnostics & Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of scleroderma and the need for effective diagnostic techniques and therapies
    • Growing awareness about scleroderma condition and emphasis on early diagnosis
    • Rising number of clinical trials for the development of novel drugs and therapies
  • Market Restraints
    • High cost associated with scleroderma treatment
  • Market Opportunities
    • Advancements in diagnostic technologies, such as imaging techniques and biomarker identification
    • Ongoing research for identifying efficient treatment options for scleroderma
  • Market Challenges
    • Side effects associated with the drugs used in scleroderma treatment

Porter's Five Forces: A Strategic Tool for Navigating the Scleroderma Diagnostics & Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Scleroderma Diagnostics & Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Scleroderma Diagnostics & Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Scleroderma Diagnostics & Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Scleroderma Diagnostics & Therapeutics Market

A detailed market share analysis in the Scleroderma Diagnostics & Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Scleroderma Diagnostics & Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Scleroderma Diagnostics & Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Scleroderma Diagnostics & Therapeutics Market

A strategic analysis of the Scleroderma Diagnostics & Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Scleroderma Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Antibodies Inc., AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, Inc, Biogen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd., Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Myriad Genetics, Inc, Novartis AG, PerkinElmer Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Takeda Pharmaceutical Company Limited, The Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., and Trinity Biotech plc..

Market Segmentation & Coverage

This research report categorizes the Scleroderma Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diagnostic Tests, market is studied across Blood Tests, Imaging, Pulmonary Function Tests, and Skin Biopsies. The Imaging is further studied across CT Scans, MRI, and X-rays.
  • Based on Drug Type, market is studied across Calcium Channel Blockers, Chelating Agents, Corticosteroids, Endothelin Receptor Agonists, Immunosuppressive Agents, PDE-5 Inhibitors, and Prostacyclin Analogues.
  • Based on Therapeutics, market is studied across Biologic Therapies, Gene Therapy, Pulmonary Fibrosis Treatments, Raynaud's Phenomenon Management, and Stem Cell Transplantation.
  • Based on Indication, market is studied across Localized and Systemic.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of scleroderma and the need for effective diagnostic techniques and therapies
      • 5.1.1.2. Growing awareness about scleroderma condition and emphasis on early diagnosis
      • 5.1.1.3. Rising number of clinical trials for the development of novel drugs and therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with scleroderma treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in diagnostic technologies, such as imaging techniques and biomarker identification
      • 5.1.3.2. Ongoing research for identifying efficient treatment options for scleroderma
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the drugs used in scleroderma treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Scleroderma Diagnostics & Therapeutics Market, by Diagnostic Tests

  • 6.1. Introduction
  • 6.2. Blood Tests
  • 6.3. Imaging
    • 6.3.1. CT Scans
    • 6.3.2. MRI
    • 6.3.3. X-rays
  • 6.4. Pulmonary Function Tests
  • 6.5. Skin Biopsies

7. Scleroderma Diagnostics & Therapeutics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Calcium Channel Blockers
  • 7.3. Chelating Agents
  • 7.4. Corticosteroids
  • 7.5. Endothelin Receptor Agonists
  • 7.6. Immunosuppressive Agents
  • 7.7. PDE-5 Inhibitors
  • 7.8. Prostacyclin Analogues

8. Scleroderma Diagnostics & Therapeutics Market, by Therapeutics

  • 8.1. Introduction
  • 8.2. Biologic Therapies
  • 8.3. Gene Therapy
  • 8.4. Pulmonary Fibrosis Treatments
  • 8.5. Raynaud's Phenomenon Management
  • 8.6. Stem Cell Transplantation

9. Scleroderma Diagnostics & Therapeutics Market, by Indication

  • 9.1. Introduction
  • 9.2. Localized
  • 9.3. Systemic

10. Americas Scleroderma Diagnostics & Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Scleroderma Diagnostics & Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Antibodies Inc.
  • 4. AstraZeneca plc
  • 5. Bayer AG
  • 6. Bio-Rad Laboratories, Inc
  • 7. Biogen Inc.
  • 8. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 9. Eli Lilly and Company
  • 10. Exagen Inc.
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Galapagos NV
  • 13. Gilead Sciences, Inc.
  • 14. GlaxoSmithKline plc (GSK)
  • 15. Merck & Co., Inc.
  • 16. Myriad Genetics, Inc
  • 17. Novartis AG
  • 18. PerkinElmer Inc.
  • 19. Pfizer Inc.
  • 20. Regeneron Pharmaceuticals, Inc.
  • 21. Sanofi Genzyme
  • 22. Takeda Pharmaceutical Company Limited
  • 23. The Bristol-Myers Squibb Company
  • 24. Thermo Fisher Scientific Inc.
  • 25. Trinity Biotech plc.

LIST OF FIGURES

  • FIGURE 1. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CT SCANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY X-RAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHELATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ENDOTHELIN RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PDE-5 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PROSTACYCLIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PULMONARY FIBROSIS TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RAYNAUD'S PHENOMENON MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LOCALIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 243. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023